- Home
- CHCO vs ELVN Comparison
CHCO vs ELVN Comparison
Compare CHCO & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHCO | ELVN |
|---|---|---|
| Founded | 1957 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CHCO | ELVN |
|---|---|---|
| Price | $143.90 | $52.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $132.50 | $43.40 |
| AVG Volume (30 Days) | 142.2K | ★ 878.5K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | ★ 13.18 | 3.17 |
| EPS | ★ 2.20 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.16 | N/A |
| Revenue Next Year | $3.12 | N/A |
| P/E Ratio | $63.46 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $113.21 | $14.79 |
| 52 Week High | $140.27 | $54.88 |
Technical Indicators
Market Signals| Indicator | CHCO | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 69.48 | 62.82 |
| Support Level | $120.61 | $25.63 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 3.24 | 2.46 |
| MACD | 0.44 | -0.15 |
| Stochastic Oscillator | 91.82 | 78.13 |
Price Performance
Historical ComparisonAbout CHCO City Holding Company
City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.